FundedIQ
Biotechnology

CartilaGen: Funding, Investors & Team (Sep 2026)

An intra-articular injection of a small-molecule medication designed to fend off post-traumatic osteoarthritis is being developed by CartilaGen Inc. The goal of CartilaGen's solution is to fill an unmet medical need in one field of medicine by offering an unprecedented disease-modifying medication.

CartilaGen.com LinkedIn Coralville, United States 1-10 employees
Biotechnology Health CareOsteoarthritis Biomaterials And preventative medicine
Total raised
$130k
Rounds
1
Latest
Undisclosed round
Nov 2022

CartilaGen has raised $130k across 1 funding round on record, the most recent an undisclosed round of $130k announced in Nov 2022.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

CartilaGen Company Profile and Key Stats

Total funding raised
$130k
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$130k in Nov 2022
Employees
1-10
reported band
Headquarters
Coralville, United States

Latest funding round on record: Nov 2022.

CartilaGen Funding Rounds

Date
Round
Amount
Undisclosed round
$130k

CartilaGen Founders and Leadership Team

Name
Role
Contact
Jaison Marks
CEO

No contact details are on record for this team yet.

CartilaGen Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,183
$8.0M
29,878
$7.5M

CartilaGen's latest round of $130k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like CartilaGen in Biotechnology and Coralville

Companies Similar to CartilaGen

SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…

Undisclosed round $960k

DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…

Series B $4.0M

Solstice Oncology is a clinical stage immuno-oncology company

Series A $225M

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…

Series F $275M

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…

Series A $116M

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

CartilaGen Funding FAQs

What does CartilaGen do?

An intra-articular injection of a small-molecule medication designed to fend off post-traumatic osteoarthritis is being developed by CartilaGen Inc. The goal of CartilaGen's solution is to fill an unmet medical need in one field of medicine by offering an unprecedented disease-modifying medication.

How much funding has CartilaGen raised?

CartilaGen has raised $130k across 1 round on record. The most recent is an undisclosed round of $130k announced in Nov 2022.

When did CartilaGen last raise funding?

CartilaGen's most recent funding round on record is an undisclosed round of $130k, announced in Nov 2022.

Who is the CEO of CartilaGen?

Jaison Marks is listed as CEO at CartilaGen.

Where is CartilaGen headquartered?

CartilaGen is based in Coralville, Iowa, United States.

How many employees does CartilaGen have?

CartilaGen is in the 1-10 employee band.

How does CartilaGen's funding compare to other Biotechnology startups?

CartilaGen's latest round of $130k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's CartilaGen Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CartilaGen is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.